Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

MARK H TABOR

Allopathic & Osteopathic Physicians Otolaryngology

NPI
1467465153
CMS profile
433518
Location
TAMPA, FL

General Payments · PY2018–2024

$26,434.06

  • Reported across 63 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$8,690.91

12 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Medtronic, Inc. $3,919.06 7
Regeneron Pharmaceuticals, Inc. $2,850.00 1
GENZYME CORPORATION $1,678.78 2
DePuy Synthes Sales Inc. $148.96 1
BAXTER HEALTHCARE $94.11 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $705.43 10
PY2019 $2,675.29 9
PY2020 $6,853.82 13
PY2021 $3,565.61 5
PY2022 $1,194.05 7
PY2023 $2,748.95 7
PY2024 $8,690.91 12

Payment records · PY2024 (12)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Baxter Healthcare $94.11 04/30/2024 Food and Beverage Undisputed 01/23/2026 1120587872 CMS
DePuy Synthes Sales Inc. $148.96 11/10/2024 Food and Beverage Undisputed 01/23/2026 1077827782 CMS
GENZYME CORPORATION $1,664.00 10/17/2024 Consulting Fee Undisputed 01/23/2026 1139698092 CMS
GENZYME CORPORATION $14.78 12/11/2024 Food and Beverage Undisputed 01/23/2026 1139698086 CMS
Medtronic, Inc. $240.89 02/13/2024 Food and Beverage Undisputed 01/23/2026 1119330651 CMS
Medtronic, Inc. $1,260.00 03/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1112050457 CMS
Medtronic, Inc. $104.71 04/11/2024 Food and Beverage Undisputed 01/23/2026 1119330657 CMS
Medtronic, Inc. $108.85 07/12/2024 Food and Beverage Undisputed 01/23/2026 1119330653 CMS
Medtronic, Inc. $73.79 07/13/2024 Food and Beverage Undisputed 01/23/2026 1119330655 CMS
Medtronic, Inc. $30.82 07/24/2024 Travel and Lodging Undisputed 01/23/2026 1112050461 CMS
Medtronic, Inc. $2,100.00 07/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1112050459 CMS
Regeneron Pharmaceuticals, Inc. $2,850.00 04/26/2024 Consulting Fee Undisputed 01/23/2026 1114405701 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.